SCHEMBL31145984

SCHEMBL31145984

COc1nccc2[nH]c(=O)c(C(C)C(=O)O)c(O)c12

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 6/20 0.35
▸ KDM5A P29375 1/20 0.33
▸ KDM4E B2RXH2 5/20 0.31
▸ MAPT P10636 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ SMN1; SMN2 Q16637 2/20 0.31
▸ ALDH1A1 P00352 2/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ NLRP3 Q96P20 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ IDH1 O75874 1/20 0.31
▸ HPGD P15428 2/20 0.31
▸ HSD17B10 Q99714 2/20 0.31
▸ BTK Q06187 1/20 0.30
▸ DAO P14920 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31146216 0.89 KDM5A (0.35) LRRK2KDM5AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL31145941 0.84 IDO1 (0.35) LRRK2CYP2C19POLB
SCHEMBL31145955 0.76 PDE3B (0.41) KDM5AKDM4EMAPTCYP2C19SMN1; SMN2
SCHEMBL31146209 0.74 LRRK2 (0.35) LRRK2KDM4ECYP2C19SMN1; SMN2ALDH1A1
SCHEMBL31145856 0.71 CXCR2 (0.33) LRRK2POLBIDH1
SCHEMBL31145911 0.69 PTGS2 (0.32) MAPTMEN1KMT2A
SCHEMBL31146055 0.68 PDE3B (0.38) KDM5AKDM4EMAPTSMN1; SMN2ALDH1A1
SCHEMBL31145950 0.67 BRD4 (0.36) KDM5AMAPTSMN1; SMN2ALDH1A1MEN1
SCHEMBL31145968 0.65 PARP1 (0.47) KDM5APOLBDAO
SCHEMBL30340590 0.65 PTGS2 (0.38) KDM4ECYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688748-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2026-02-11 — — EP disclosed
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2026-01-08 — — US disclosed
US-12448369-B2 Quinolinone amide compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-10-21 — — US disclosed
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 — — US disclosed
WO-2024206339-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12448369-B2 Quinolinone amide compounds and uses thereof TNNI3, TNNT2, COQ8A LRRK2 2957/4885KDM5A 3091/4885KDM4E 3988/4885
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, COQ8A LRRK2 2957/4885KDM5A 3091/4885KDM4E 3988/4885
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNT2, TNNI3, TNNC1 LRRK2 3161/4885KDM5A 3803/4885KDM4E 4379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback